Enjoy complimentary customisation on priority with our Enterprise License!
The anti-thrombin III testing market size is forecast to increase by USD 87.8 million, at a CAGR of 4.51% between 2023 and 2028. The growth of the market hinges on several key factors. The existence of tests related to anti-thrombin III addresses critical health concerns, aiding in the diagnosis and management of thrombotic disorders. Concurrently, the increase in the number of people diagnosed with hypertension drives demand for diagnostic tests that can accurately monitor blood pressure levels and assess cardiovascular health. Furthermore, there is a notable shift toward rapid diagnostics, driven by the need for timely and efficient healthcare interventions. These advancements in diagnostic technology enable quicker disease detection, prompt treatment decisions, and improved patient outcomes. As healthcare systems prioritize efficiency and accuracy, the market for diagnostic tests is poised to expand, catering to the growing global demand for accessible and effective medical diagnostics.
For More Highlights About this Report, Request Free Sample
The market is crucial for diagnosing conditions like hereditary antithrombin deficiency and assessing risks related to thrombosis in cardiovascular diseases. Key players like Octapharma and Atenative are advancing plasma-derived antithrombin concentrate therapies within the therapeutics segment. Acta Haematologica and the British Heart Foundation contribute to research and education on AT III deficiency and clotting disorders. Advancements in artificial intelligence enhance activity and immunological assays, improving accuracy in hospital, research institute, and clinic settings. Point-of-care testing facilitates faster diagnoses, supporting personalized medicine approaches. As demand grows for precise blood tests such as LMWH monitoring and alternative names for functional antithrombin III, the market is poised for expansion, meeting critical healthcare needs with innovative diagnostic solutions.
Existence of tests related to anti-thrombin III is notably driving market growth. Anti-thrombin III testing plays a crucial role in diagnosing and managing anti-thrombin deficiency, a condition characterized by the formation of excessive blood clots in the veins. This testing encompasses various related assessments, including the Prothrombin time (PT) test, also known as the PT-International Normalized Ratio (INR) test. The PT test measures the time it takes for the blood plasma to form a clot, which is essential in determining the appropriate anticoagulant dosage and, in some instances, evaluating liver disorders.
Moreover, the testing equipment for anti-thrombin III analysis comes in varying platform sizes and capacities. Compatibility with different medical gas cylinders and durability are essential factors when selecting testing instruments. Maintenance requirements are also crucial to ensure accurate and consistent results. Success stories and real-world scenarios demonstrate the tangible benefits of effective anti-thrombin III testing, enabling healthcare professionals to optimize patient care and improve outcomes in heavy material handling and ground-level operations. Thus, such factors are driving the growth of the market during the forecast period.
Presence of various blood clotting disorders is the key trend in the market. Anti-thrombin III testing plays a crucial role in diagnosing anti-thrombin deficiency, a condition characterized by decreased levels of this essential coagulation inhibitor in the blood. This deficiency can lead to various symptoms, including the formation of blood clots and pulmonary emboli, which are similar to those seen in other disorders such as antiphospholipid syndrome and protein S deficiency. Protein C deficiency, an inherited disorder, is one such condition where patients exhibit approximately half the normal level of this vitamin K-dependent coagulation factor in their blood. Consequences of this deficiency include the development of pulmonary emboli and blood clots in the deep veins of the legs and in the venous sinuses of the brain.
However, when selecting an anti-thrombin III testing platform, considerations such as lifting capacity, platform size, compatibility, durability, and maintenance requirements are essential. Case studies and success stories provide tangible benefits and real-world scenarios of the effective use of these testing systems. For instance, during operations involving medical gas cylinders and handling heavy materials at ground level, a robust testing platform with minimal maintenance requirements is advantageous. By ensuring compatibility with various sample types and ease of use, these systems contribute significantly to the efficient and accurate diagnosis of anti-thrombin deficiency. Thus, such trends will shape the growth of the market during the forecast period.
Lack of clinically available protocols to treat anti-thrombin deficiency is the major challenge that affects the growth of the market. In the medical field, the administration of anti-thrombin III (AT III) plays a crucial role in preventing thrombosis during surgeries or high-risk situations where heparin is contraindicated. However, the optimal use of AT III concentrates is a subject of debate among hematologists due to limited clinical studies. These concentrates are administered intravenously to ensure an adequate level of AT III in the bloodstream, thereby enhancing the effectiveness of heparin. This is particularly important in neurosurgery, severe trauma, and child delivery, where the risk of venous clots is high.
Further, the choice of an AT III testing platform is a critical decision for healthcare providers, considering factors such as lifting capacity, platform size, compatibility with medical gas cylinders, durability, and maintenance requirements. Case studies and success stories demonstrate the tangible benefits of using advanced AT III testing systems, which enable efficient and accurate testing in real-world scenarios. For instance, these systems can process heavy materials at ground level, ensuring a streamlined workflow and reducing the risk of errors. By investing in reliable and robust AT III testing equipment, healthcare providers can ensure the best possible patient outcomes while minimizing operational costs. Hence, the above factors will impede the growth of the market during the forecast period
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Abbott Laboratories - The company offers anti-thrombin III testing products such as CP3000 lab auto system assembly kit.
The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The hospitals segment is estimated to witness significant growth during the forecast period. The market plays a crucial role in ensuring the safety and productivity of businesses involved in the transportation sector. This includes lorry operators, freight carriers, and construction companies, among others. The loading and unloading process at the dock involves the use of various equipment such as forklift trucks, hydraulic and pneumatic cylinders, and electric relay switches. These machines are essential for lifting goods from the vehicle load bed or van and transferring them to the truck or loading platform. The efficient functioning of these machines is critical to minimize workplace injuries, accidents, and damage to goods during loading and unloading. An automated system can significantly enhance business productivity and reduce insurance costs associated with workplace accidents.
Get a glance at the market share of various regions Download the PDF Sample
The hospitals segment was the largest and was valued at USD 134.50 million in 2018. The truck, road, and loading environment can impact the hydraulic and mechanical components of these machines, requiring regular repairs and maintenance. Factors such as labor costs, fuel efficiency, and long-term savings are essential considerations for businesses in the transportation sector. Damage to goods during loading and unloading can result in significant financial losses. Therefore, investing in regular testing and maintenance of AT III levels in hydraulic and pneumatic systems is a wise investment for lorry operators, freight carriers, and businesses dealing with cargo transportation.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 46% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The market plays a crucial role in ensuring safety and productivity in various industries, particularly those involving the loading and unloading of goods from vehicles. This market caters to the needs of business operators, forklift truck drivers, and lorry operators in sectors such as construction, waste management, and freight carriers. The loading and unloading process at a loading dock or vehicle load bed involves the use of hydraulic, pneumatic, mechanical, or electric relay switches to operate hydraulic cylinders in lifting platforms. These platforms facilitate the loading and unloading of cargo from trucks, vans, articulated lorries, and other vehicles. Ensuring the smooth functioning of these systems is essential to prevent workplace injuries, accidents, and damage to goods.
Moreover, investing in automated systems for loading and unloading can lead to long-term savings through increased business productivity, reduced labor costs, improved fuel efficiency, and lower insurance costs. In the context of construction and cargo transportation, the timely and efficient loading and unloading of vehicles is vital for project deadlines and customer satisfaction. Factors to consider when implementing AT III testing include the type and size of the vehicle fleet, the nature of the cargo being transported, and the working environment. Regular testing and maintenance of these systems can help prevent unexpected breakdowns, minimize damage to goods, and ensure the safety of personnel involved in the loading and unloading process.
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Million" for the period 2024 to 2028, as well as historical data from 2018 to 2022 for the following segments.
You may also interested in below market reports:
The market plays a critical role in managing thrombosis-related disorders such as deep vein thrombosis (DVT) and pulmonary embolism. Testing involves activity assays to assess levels related to SERPINC1 gene mutations and factor V Leiden, aiding in thrombosis management. Healthcare providers use blood samples to conduct antithrombin antigen and activity tests, crucial for diagnosing genetically inherited antithrombin deficiencies and bleeding disorders. Test results help identify abnormalities like excessive bleeding tendencies or clot formation in arteries, guiding treatment decisions for conditions associated with liver failure, kidney disease, and cancer metastasis. Despite potential discomforts like pain or bruising from needles, timely testing is essential to prevent complications like hematoma or infection. As research progresses in thrombosis updates published in journals like Frontiers in Neurology and NSO, advancements in testing technologies promise improved diagnostic accuracy and patient outcomes.
Market Scope |
|
Report Coverage |
Details |
Page number |
153 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 4.51% |
Market growth 2024-2028 |
USD 87.8 million |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
4.24 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 46% |
Key countries |
US, Germany, China, UK, and Canada |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Abbott Laboratories, Beckman Coulter Inc., Becton Dickinson and Co., Bio Rad Laboratories Inc., BIRON HEALTH GROUP, Danaher Corp., F. Hoffmann La Roche Ltd., Grifols SA, Invitae Corp., Merck KGaA, Meridian Bioscience Inc., Oy Medix Biochemica Ab, Randox Laboratories Ltd., Scripps Laboratories Inc., Sekisui Diagnostics LLC, Siemens AG, Sysmex Corp., Thermo Fisher Scientific Inc., Transasia Bio Medicals Ltd., and Werfenlife SA |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the market forecast period |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.